7WI0
SARS-CoV-2 Omicron variant spike in complex with three human neutralizing antibodies
7WI0 の概要
| エントリーDOI | 10.2210/pdb7wi0/pdb |
| EMDBエントリー | 32517 |
| 分子名称 | Spike protein S1, XMA04 heavy chain variable domain, XMA01 heavy chain variable domain, ... (8 entities in total) |
| 機能のキーワード | sars-cov-2, omicron, spike protein, neutralizing antibody, cryo-em, viral protein |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 7 |
| 化学式量合計 | 97148.90 |
| 構造登録者 | |
| 主引用文献 | Wang, S.,Sun, H.,Zhang, Y.,Yuan, L.,Wang, Y.,Zhang, T.,Wang, S.,Zhang, J.,Yu, H.,Xiong, H.,Tang, Z.,Liu, L.,Huang, Y.,Chen, X.,Li, T.,Ying, D.,Liu, C.,Chen, Z.,Yuan, Q.,Zhang, J.,Cheng, T.,Li, S.,Guan, Y.,Zheng, Q.,Zheng, Z.,Xia, N. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Rep, 39:110862-110862, 2022 Cited by PubMed Abstract: The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL). nAb XMA09 shows weak but unattenuated neutralization against all variants of concern (VOCs) as well as SARS-CoV. Structural analysis reveals that the above three antibodies could synergistically bind to the receptor-binding domains (RBDs) of both wild-type and Omicron spikes and defines the critical determinants for nAb-mediated broad neutralizations. Three nAbs confer synergistic neutralization against Omicron, resulting from the inter-antibody interaction between XMA04 and XMA01(or XMA09). Furthermore, the XMA01/XMA04 cocktail provides synergistic protection against Beta and Omicron variant infections in hamsters. In summary, our results provide insights for the rational design of antibody cocktail therapeutics or universal vaccines against Omicron. PubMed: 35594869DOI: 10.1016/j.celrep.2022.110862 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (3.82 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






